ADMA Biologics Rejects Short-Seller Claims, Citing Strong ASCENIV Demand and Industry-Standard Inventory
ADMA sits 15% above its 52-week low of $7.21 on elevated volume (8.2× avg).
Summary
ADMA Biologics has issued a comprehensive statement refuting the allegations made by short-seller Culper Research on March 24, 2026. The company provided detailed data to counter claims of channel stuffing, competitive positioning, and inventory levels for its immune globulin products, ASCENIV and BIVIGAM. ADMA highlighted growing end-user demand for ASCENIV and presented inventory data from distributors showing levels consistent with industry standards, directly addressing the short report's assertions. Furthermore, ADMA clarified ASCENIV's role as a late-line therapy for immune-compromised patients, justifying its premium pricing and distinct market position. This detailed response, which follows a general announcement of a response on March 25 and is likely concurrent with a formal 8-K filing, aims to alleviate market confusion and restore investor confidence by providing specific evidence against the short-seller's claims.
At the time of this announcement, ADMA was trading at $8.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $7.21 to $25.67. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.